Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Luvesilocin

Add links
From Wikipedia, the free encyclopedia
(Redirected from FT-104)

Luvesilocin
Clinical data
Other namesRE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Routes of
administration		Oral, subcutaneous injection[1][2]
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Metabolites• 4-HO-DiPT[2]
Onset of action≤1 hour (s.c.Tooltip subcutaneous injection)[2]
Elimination half-life• Luvesilocin: 0.43–0.64 hours (s.c.Tooltip subcutaneous injection)[1][2]
• 4-HO-DiPT: 2.7–4.1 hours (s.c.Tooltip subcutaneous injection)[1][2]
Duration of action3.6 hours (range ~3–4 hours) (s.c.Tooltip subcutaneous injection)[1][2]
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H30N2O4
Molar mass374.481 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders.[3][4] It is taken orally or by subcutaneous injection.[3][2]

The drug is a prodrug ester of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor.[5][6]

Luvesilocin was first described in the literature in 2021.[5][7] It is under development for the treatment of postpartum depression and treatment-resistant depression.[8][9][10][11] As of September 2025, the drug has reached phase 2 clinical trials.[12] A phase 3 trial is planned for 2026.[12]

Use and effects

[edit]
Luvesilocin (RE104; 4-GO-DiPT) Drug Effects Questionnaire (DEQ) "feel high" ratings at doses of 5 to 40 mg via subcutaneous injection over 6 hours.[2]

The effects of luvesilocin have been clinically studied.[2] It was evaluated at doses of 5 to 40 mg (equivalent to ~4–32 mg 4-HO-DiPT) by subcutaneous injection in this study.[2] The drug was specifically assessed in terms of modified Drug Effects Questionnaire (DEQ) ratings, Mystical Experience Questionnaire (MEQ) ratings, and adverse effects.[2] The mean duration of the psychedelic experience after administration of luvesilocin at a dose of 30 mg was found to be 3.6 hours.[2][1]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT.[13][14] This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[5][6] Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics.[citation needed]

4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[15] In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT).[16]

The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.[5][6]

Pharmacokinetics

[edit]

Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64 hours and of 4-HO-DiPT is 2.7 to 4.1 hours.[2] The mean duration with this route at the employed dose was 3.6 hours.[2]

Chemistry

[edit]

Synthesis

[edit]

The chemical synthesis of luvesilocin has been described.[13]

Analogues

[edit]

Analogues of luvesilocin include 4-HO-DiPT (iprocin), 4-AcO-DiPT (ipracetin), 4-PrO-DiPT, 4-AcO-DMT (psilacetin), 4-PrO-DMT, and 4-GO-DMT (RE-109), among others.

History

[edit]

Luvesilocin was first described in the literature in 2021.[5][7]

Society and culture

[edit]

Names

[edit]

Luvesilocin is the generic name of the drug and its INNTooltip International Nonproprietary Name.[17] It is also known by its developmental code names RE104 or RE-104 and FT104 or FT-104.[3]

[edit]

Canada

[edit]

Luvesilocin is not a controlled substance in Canada as of 2025.[18]

United States

[edit]

Luvesilocin is not an explicitly controlled substance in the United States.[19] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

Research

[edit]

Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders.[3][1][20][21] As of September 2025, it has reached phase 2 clinical trials for these indications.[12] A phase 3 trial is planned for 2026.[12] The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).[3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 Pollack M, Hocevar-Trnka J, Bryson N, Taylor B, Johnson M, Alexander R (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P697. RE104: A Novel, Shorter-Acting Psychedelic for Post Partum Depression". Neuropsychopharmacology. 49 (Suppl 1): 418–594 (469–470). doi:10.1038/s41386-024-02013-y. PMID 39643635.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Ludbrook G, Bryson N, Taylor B, Hocevar-Trnka J, Johnson MW, Hirman J, et al. (2025). "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study". J Clin Psychopharmacol. 45 (5): 441–453. doi:10.1097/JCP.0000000000002047. PMC 12379775. PMID 40685873.
  3. 1 2 3 4 5 "RE 104". AdisInsight. 23 September 2025. Retrieved 8 October 2025.
  4. ↑ Braner S (May 8, 2024). "Reunion Neuroscience raises $103 million for a psychedelic to treat depression". Chemical & Engineering News.
  5. 1 2 3 4 5 "4-HO-DiPT". Psychedelic Science Review. 23 June 2022. Retrieved 8 October 2025.
  6. 1 2 3 Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, et al. (April 2024). "Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala". Neuropsychopharmacology. 49 (5): 854–863. doi:10.1038/s41386-023-01744-8. PMC 10948882. PMID 37752222.
  7. 1 2 Bryson N. Tryptamine prodrugs. US 2021/0403425 A1, Field Trip Psychedelics, Inc0. Published online April 5, 2022. Accessed May 27, 2022. https://patents.google.com/patent/US11292765B2/en?q=field+trip+health&assignee=Field+Trip+Psychedelics+Inc.
  8. ↑ Hallifax J (11 August 2022). "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
  9. ↑ WO 2022/000091, Bryson N, "Tryptamine prodrugs", published 6 January 2022, assigned to Field Trip Psychedelics Inc.
  10. ↑ US 2022/0024956, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.", published 27 January 2022, assigned to Mindset Pharma Inc.
  11. ↑ WO 2022/246572, Slassi A, Araujo J, Higgin GH, Gabriele J, "Hallucinogen-Fatty Acid Combination", published 1 December 2022, assigned to Mindset Pharma Inc.
  12. 1 2 3 4 Alexander R, Hocevar-Trnka J (June 26, 2024). "RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression". psychiatrictimes.com.
  13. 1 2 Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chemical Neuroscience. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC 11191588. PMID 38758589.
  14. ↑ "Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.
  15. ↑ Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC 8033608. PMID 33860183.
  16. ↑ Gatch MB, Hoch A, Carbonaro TM (April 2021). "Discriminative Stimulus Effects of Substituted Tryptamines in Rats". ACS Pharmacology & Translational Science. 4 (2): 467–471. doi:10.1021/acsptsci.0c00173. PMC 8033599. PMID 33860176.
  17. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). www.cdn.who.int. Retrieved 18 September 2025.
  18. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  19. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
  20. ↑ Reunion Neuroscience Inc (2025-03-06). A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
  21. ↑ Reunion Neuroscience Inc (2025-03-06). A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Luvesilocin&oldid=1353945817"